Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 375 results
Press release cover image

Oct 23, 2026

Biointron Introduces RushDATA™ to Accelerate Wet-Lab Validation for AI-Driven Antibody Discovery

· 1-day CHO expression and rapid characterization help close the gap between computational design and experimental validation· 20,000+ molecules per week capacity supports large-scale screening of AI-generated antibody candidates· Integrated binding and developability assessments generate standardized, multidimensional datasets for candidate selection and AI/ML workflowsCAMBRIDGE, Mass.--(BIOSPACE)-- Biointron BiologicalUSA Inc. ("Biointron"), a leading contract research organizationspecializing
A petri dish with a protein sample in a lab setting

Oct 22, 2026

Nvidia, UW Institute for Protein Design Unveil Open-Source Protein Design AI Model

The University of Washington's Institute for Protein Design has collaborated with Nvidia to launch RFD4-Proteina, a groundbreaking open-source AI model aimed at revolutionizing protein design.RFD4-Proteina leverages Nvidia’s BioNeMo platform, enhancing the ability to create proteins with specific functionalities through advanced biomolecular reasoning. The model allows researchers to generate and refine protein designs rapidly, achieving significantly higher success rates compared to previous me
Press release cover image

Oct 22, 2026

Founded by MIT and Flagship Alum, AI Drug Discovery Company Reflector Bio Emerges from Stealth

New York, NY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Reflector Bio, founded by MIT-trained computational biologist and early employee at Flagship Pioneering's Cellarity, Yuge Ji, today emerged from stealth with an AI drug discovery model that aims to make precision medicine faster and more affordable.  Reflector Bio founder and computational biologist, Yuge Ji. Reflector has built what is, to its knowledge, the largest phenotypic model to date by experimental volume. Its platform has previously b
Press release cover image

Oct 22, 2026

Genedata Expands AI Discovery Workflows with NVIDIA BioNeMo Open Models, Including the New RFD4-Proteina Release

Bringing next-generation binder design models into production discovery BASEL, Switzerland, Oct. 22, 2026 /PRNewswire/ -- Genedata, a Danaher company, and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the addition of the new RFD4-Proteina binder design model into Genedata's AI-enabled discovery workflows, following the model's introduction at NVIDIA GTC Berlin. As an early ecosystem partner, Genedata is among the first companies to make RFD4
Press release cover image

Oct 22, 2026

Asimov Announces Adoption of Its AI-Driven Cell Line Development Platform by LG Chem

Asimov’s CHO Edge System, including the recently announced Chrysalis transposase and Kernel, Asimov’s AI-driven genetic design software, will support LG Chem’s biologics cell line development activitiesBOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a licensing agreement with South Korea-based LG Chem, a leading global chemical company with a diversified business portfolio spanning
A molecular model on a petri dish in a dim laboratory setting

Oct 22, 2026

AI-Generated Evidence in Drug Discovery: Reliability, Legal Risk & FDA Compliance

The integration of artificial intelligence (AI) in drug discovery poses significant challenges regarding the reliability of AI-generated evidence, particularly concerning regulatory compliance and legal risks.AI models utilized in drug development are fundamentally probabilistic, which means they can produce outputs that may seem plausible yet be incorrect. This issue is exacerbated by three primary flaws: reliance on incomplete datasets, the opaque nature of AI reasoning, and sensitivity to min
A pipette on a lab bench surrounded by vials and petri dishes in a busy laboratory setting.

Oct 21, 2026

Using AI Agents and Bio-Foundation Models to Automate Vector Design for Cell Line Development

Asimov is leveraging AI and bio-foundation models to enhance vector design, revolutionizing cell line development.In a recent webinar, Jamie Freeman, PhD, Asimov's VP of Business Development and Commercial Strategy, discussed the limitations of traditional drug development processes, which often rely on empirical methods and extensive screening of candidates. He emphasized that as the industry shifts towards more complex formats, such as bispecifics, the conventional trial-and-error approach bec
Press release cover image

Oct 21, 2026

iReprogram Partners with University of Michigan on Multimillion-Dollar Initiative to Reprogram Cells for Diabetes

Backed by the Look to Michigan Strategic Initiative Fund, the collaboration aims to accelerate patient-derived cell therapies to pioneer comprehensive diabetes treatments.ANN ARBOR, Mich., Oct. 21, 2026 /PRNewswire/ --  iReprogram, spun out of the University of Michigan (U-M), was named lead industry partner in the newly launched Michigan Initiative to Reprogram Cells for Diabetes (MIRC-D). Supported by the U-M Strategic Initiative Fund, the multimillion-dollar effort unites experts across seven
A minimalist representation of a lipid nanoparticle and drug molecule.

Oct 21, 2026

AI meets big pharma: METiS partners with Lilly to reinvent drug delivery

METiS TechBio has entered a significant partnership with Eli Lilly, valued at $1.1 billion, to innovate drug delivery through AI-enhanced lipid design.This collaboration focuses on developing advanced lipid nanoparticle (LNP)-based delivery systems, aiming for more accurate and tissue-specific therapeutic delivery. METiS will receive an initial payment in the low double-digit millions, alongside potential milestone payments and royalties based on the sales of resultant products. Central to this
Minimalist illustration of a protein structure

Oct 21, 2026

NVIDIA releases a tool to help scientists design new proteins, with possible uses in medicine.

NVIDIA has unveiled a new tool, RFD4-Proteina, aimed at revolutionizing protein design, which could significantly impact drug discovery and cancer treatment.The collaboration between NVIDIA and the UW Medicine Institute for Protein Design has led to the introduction of RFD4-Proteina, an open model designed to enhance the process of creating new proteins. This model allows scientists to generate targeted protein designs by utilizing molecular inputs and scoring objectives, thereby streamlining th
A miniprotein in a test tube on a lab bench in a dimly lit laboratory.

Oct 21, 2026

Astellas links up with AI Proteins in $400M computational d rugdiscovery deal

Japan's Astellas Pharma has entered a significant partnership with AI Proteins, a Boston-based computational discovery firm, in a deal potentially valued at $400 million aimed at revolutionizing drug discovery.AI Proteins specializes in creating miniproteins using a computational design platform that allows for the development of novel molecules tailored for specific therapeutic functions. This approach contrasts with traditional methods that rely on naturally occurring biologics. According to A
A minimalist illustration of a pill and a virus, symbolizing antiviral drug discovery.

Oct 21, 2026

Inside the ‘Public Library of Blueprints’: How the ASAP Discovery Consortium Turned Open Science Into an Antiviral Pipeline

The ASAP Discovery Consortium has redefined drug discovery through an innovative open-science model, earning recognition for its efforts to create a collaborative antiviral pipeline.In a recent presentation at the Bio-IT World Conference & Expo, Nick Lynch, a leader in the project, detailed the consortium's journey of establishing a global network of 20 institutes focused on antiviral development. This initiative, born from the lessons of the COVID-19 pandemic, aims to produce clinic-ready antiv